Michael Makris/LinkedIn
Jun 18, 2026, 06:43
Michael Makris: Will New Anti-TFPI Drug Armocibat Behaves any Different to Concizumab or Marstacimab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn:
“A Chinese company called Suzhou Alphamab is making an anti-TFPI drug called armocibat, for use in haemophilia with and without inhibitors.
The drug is in phase III at present.
They have just signed a license agreement for a Russian company called Nanolek to produce the drug.
I have no reason to believe that armocibat behaves any different to concizumab or marstacimab, but I hope they have safety surveillance systems to monitor for thrombosis when this drug is no longer in clinical trials.”
Stay updated with Hemostasis Today.
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas Lang։ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge